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Dengue, a mosquito-born virus infection, is considered one of the most important and widespread reemerging infectious diseases in developing countries. Clinically, the infection can be asymptomatic or it can manifest as an undifferentiated febrile illness, known as dengue fever (DF) characterized by "flu-like" symptoms including fever, headaches and myalgia. Major complications are known as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), with occurrence of plasma leakage and trombocytopenia, leading to death in a significant number of cases 3 
.
Dengue is caused by dengue virus, a positive-stranded RNA virus of the family Flaviviridae. It is transmitted to humans by Aedes sp mosquitoes and are divided into four closely related but antigenically distinct serotypes from 1 to 4. Infection by one serotype does not protect the individual against infection by a second serotype of dengue virus 6 . Instead, the appearance of clinically severe infections such as DHF and DSS seems to be mostly related to subsequent infections by a virus of different serotype from that of former infection. The mechanisms involved in the pathogenesis of dengue infections remain unresolved. Epidemiological studies have shown a higher incidence of DHF/DSS in secondary infection compared with the primary one, supporting the antibody-dependent enhancement hypothesis 5 . On the other hand, variation in virulence among viral strains may account for severe dengue disease in confirmed cases of primary infection 10 . At present, in spite of many studies all over the world, no dengue vaccine is available and the prevention of infection depends mainly on mosquito vector control.
In Brazil, millions of dengue infections have been notified all over the country since 1986. In the State of São Paulo outbreaks of DF have been notified since 1987, when the first autochtonous cases by serotype 1 virus were detected. Dengue 2 virus was introduced in 1996 and nowadays both serotypes are present in many regions of the State, as in other States of the country 2, 9 .
In 1998, dengue serotype 3 was isolated in our laboratory from an imported case. The patient, a 46-year-old male, living in Limeira, traveled on May 16 th to Nicaragua, where he stayed for three months. Starting on August 14 th he had fever, headaches, myalgia, arthralgia, retro-orbital pains and diarrhea. He arrived in Brazil on August 16 th and was hospitalized in the next day. He had full recovery and was discharged on August 20 th .
The virus isolation was accomplished in C6/36 cell culture inoculated with serum collected on the 6 th day after the onset of disease symptoms. Indirect immunofluorescence assays performed with type-specific monoclonal antibodies, showed positive reaction for dengue 3 virus 4 . This serotype identification was further confirmed by polymerase chain reaction (PCR) analysis. Virus RNA isolated from infected cell culture supernatant by silica method 1 , was reverse-transcribed and amplified with oligonucleotide concensus primers developed by LANCIOTTI et al. 7 The second-round of PCR, performed with type-specific primers, detected DNA products of 290 bp, characteristic of dengue virus serotype 3 (Fig. 1) .
Dengue 3 was introduced in Nicaragua in 1994 causing a large epidemic by DF/DSS and in the following year it spread to other Central America countries and Mexico. Molecular analysis showed that this virus was genetically distinct from that one which circulated 16 years before in the Americas, but it presented the same genotype as the one isolated in the epidemic that has caused major epidemics of DHF in Sri Lanka and India 8 .
The introduction of a new dengue serotype in a susceptible population is a real threat for the occurrence of severe forms of the disease, whatever the mechanism of pathogenesis involved. That is the case of our country, where there is a great number of people who have already contracted dengue infection by serotype 1 or 2.
The isolation and characterization of dengue 3 virus in our laboratory show the necessity of constant monitoring of dengue virus serotypes circulating in our country in order to alert the health authorities of any relevant changes observed so that measures to prevent and control a new epidemic are taken.
RESUMO Primeiro isolamento de dengue 3 no Brasil de um caso importado
Os autores relatam o isolamento do vírus dengue 3 pela primeira vez no Brasil. O paciente, residente em Limeira-SP, viajou em 16 de maio de 1998 para a Nicarágua, onde permaneceu por três meses. A partir de 14 de agosto, ele apresentou febre, dor de cabeça, mialgia, artralgia, dor retro-orbital e diarréia. Ele retornou ao Brasil em 16 de agosto e foi hospitalizado no dia seguinte. O paciente teve completa recuperação, recebendo alta em 20 de agosto. O vírus foi isolado em cultura de células C6/36 inoculadas com soro colhido no 6 0 dia após o início dos sintomas. O sorotipo 3 foi identificado por imunofluorescência indireta com anticorpos monoclonais tipo-específico. O sorotipo foi posteriormente confirmado por PCR. A introdução de um novo sorotipo de dengue em uma população susceptível é uma ameaça para a ocorrência de formas severas da doença. O isolamento e a identificação do vírus dengue são de grande importância a fim de monitorar a introdução de novos sorotipos e para que medidas sejam tomadas para prevenir e controlar novas epidemias.
